NCT02864394View on ClinicalTrials.gov

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

PHASE3CompletedINTERVENTIONAL

Enrollment

425

Participants

Timeline

Start Date

September 7, 2016

Primary Completion Date

September 9, 2019

Study Completion Date

October 14, 2022

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

Pembrolizumab

Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).

DRUG

Docetaxel

Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | Biotech Hunter | Biotech Hunter